If you have been reading about REV-ERB agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-03. Numbers and descriptions here follow the published literature rather than marketing material.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
The 17th century saw the first attempts to quantify measurements of partial vacuum. Evangelista Torricelli's mercury barometer of 1643 and Blaise Pascal's experiments both demonstrated a partial vacuum. In 1654, Otto von Guericke invented the first vacuum pump and conducted his famous Magdeburg hemispheres experiment, showing that, owing to atmospheric pressure outside the hemispheres, teams of horses could not separate two hemispheres from which the air had been partially evacuated. Robert Boyle improved Guericke's design and with the help of Robert Hooke further developed vacuum pump technology. Thereafter, research into the partial vacuum lapsed until 1850 when August Toepler invented the Toepler pump and in 1855 when Heinrich Geissler invented the mercury displacement pump, achieving a partial vacuum of about 10 Pa (0.1 Torr). A number of electrical properties become observable at this vacuum level, which renewed interest in further research. While outer space provides the most rarefied example of a naturally occurring partial vacuum, the heavens were originally thought to be seamlessly filled by a rigid indestructible material called aether. Borrowing somewhat from the pneuma of Stoic physics, aether came to be regarded as the rarefied air from which it took its name, (see Aether (mythology)). Early theories of light posited a ubiquitous terrestrial and celestial medium through which light propagated. Additionally, the concept informed Isaac Newton's explanations of both refraction and of radiant heat.
Sunak later announces that the UK will send Ukraine hundreds of air defence missiles and armed drones, in addition to the Storm Shadow cruise missiles previously promised. 16 May Following a trial at Reading Crown Court, three fraudsters who supplied forged passports to some of the UK's most notorious criminals, are sentenced to prison. Data produced by the Office for National Statistics indicates the number of people not working because of a long-term health condition has reached two and a half million. The rise is attributed to an increase in mental health problems among young people, and an increase in people suffering back and neck problems as a result of working at home. Stellantis, owners of Vauxhall, Peugeot, Citroen and Fiat, urge the UK government to renegotiate parts of its Brexit trade deal, warning that the UK could lose its car industry. The company has committed to making electric vehicles in the UK, but says it may not be able to do so because of the combined effect of post-Brexit trade rules and increases in raw material costs. 17 May The Renters (Reform) Bill is introduced into Parliament. The UK government bans the issuing of licences for animal testing of chemicals used in cosmetics products. 18 May 2023 Northern Ireland local elections: Local elections are held in Northern Ireland, two weeks after the rest of the country. Figures released by HM Treasury indicate the funeral of Elizabeth II and associated events cost the UK government £162m. 19 May John Allan announces he is stepping down as chairman of Tesco following allegations over his conduct.
The Edman degradation is a very important reaction for protein sequencing, because it allows the ordered amino acid composition of a protein to be discovered. Automated Edman sequencers are now in widespread use, and are able to sequence peptides up to approximately 50 amino acids long. A reaction scheme for sequencing a protein by the Edman degradation follows; some of the steps are elaborated on subsequently.
With the invention of the Geiger gaseous ionization detector in 1913, which became the Geiger-Müller gaseous ionization detector in 1928 - named after the physicists Hans Geiger (1882-1945) and Walther Müller (1905-1979) - the individual particles or quanta of ionizing radiation could be detected and measured. Detectors developed later, such as proportional counters or scintillation counters, which not only "count" but also measure energy and distinguish between types of radiation, also became important for radiation protection. Scintillation measurement is one of the oldest methods of detecting ionizing radiation or X-rays; originally, a zinc sulfide screen was held in the path of the beam and the scintillation events were either counted as flashes or, in the case of X-ray diagnostics, viewed as an image. A scintillation counter known as a spinthariscope was developed in 1903 by William Crookes (1832-1919) and used by Ernest Rutherford (1871-1937) to study the scattering of alpha particles from atomic nuclei.
== Laboratory methods == A number of laboratory methods have been developed for cell-free fetal DNA screening for genetic defects have been developed. The main ones are (1) massively parallel shotgun sequencing (MPSS), (2) targeted massive parallel sequencing (t-MPS) and (3) single nucleotide polymorphism (SNP) based approach. A maternal peripheral blood sample is taken by venesection at about ten weeks gestation.
Sources: en.wikipedia.org
=== Gastrointestinal === NSAIDs cause an increase in the risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Elderly patients are at greater risk for serious gastrointestinal events.
=== Psychiatry === Suvorexant has been studied in the treatment of insomnia in people with psychiatric disorders such as depression and anxiety. It was reported to improve psychiatric symptoms and to decrease cortisol levels in these individuals. A phase IV clinical trial of suvorexant as an adjunct to antidepressant therapy in people with major depressive disorder and residual insomnia was underway as of 2019. Although orexin receptor antagonists including suvorexant could be useful for treatment of depression and anxiety, there is also indication that they could have harmful effects in these conditions (e.g., animal studies and suicidal ideation in clinical trials). More clinical research is needed to determine the place of orexin receptor antagonists in the treatment of people with depression and anxiety. There is interest in suvorexant and other orexin receptor antagonists in the potential treatment of substance use disorders, including alcohol use disorder, cocaine use disorder, and opioid use disorder.
Mister Donut has an orange and white logo in the likeness of a moustachioed chef. More recently, the chain developed a set of mascot characters based on its donuts. One character, "Pon de Lion" (ポン・デ・ライオン, Pon De Raion), a lion with a mane shaped like its "pon de ring" (ポン・デ・リング, Pon De Ringu) donut line, is used in Japan. In El Salvador, the mascots are five anthropomorphic doughnuts and a rooster that is used for the breakfast menu. The company uses the same logo as Japan, and the slogan is "La gran variedad" (The great variety).
== Contraindications == Contraindications of sumatriptan include history of coronary artery disease (atherosclerosis) or coronary artery vasospasm, Wolff–Parkinson–White syndrome or other cardiac accessory conduction pathway disorders, history of stroke, transient ischemic attack, or hemiplegic or basilar migraine, peripheral vascular disease, ischemic bowel disease, uncontrolled hypertension, use of another triptan or ergot-related medication within the last 24 hours, concomitant or recent use of a monoamine oxidase inhibitor (MAOI), hypersensitivity to sumatriptan, and severe hepatic impairment.
== Environmental implications == DBNPA breaks down chemically in systems rather than biologically, like pharmaceuticals do in living organisms. Both biotic and abiotic processes can cause degradation in soil and water. Half-lives in soil range from 4 to 25 hours, with pH values between 4.8 and 7.5. DBNPA is prone to photodegradation in regions exposed to sunlight and aqueous hydrolysis in moist soil. DBNPA is not expected to adsorb to sediment and suspended solids in water. In water, the primary product of degradation at pH 5 is dibromoacetic acid, while at pH 7 and 9, the primary product of degradation is dibromoacetonitrile. Additionally, it can break down into bromoacetamide, bromoacetic acid, 2-cyanoacetamide, and oxalic acid. About 4 hours is the half-life. DBNPA is prone to photodegradation. Its atmospheric fate is that the vapour-phase DBNPA is degraded in the atmosphere by photochemically-produced hydroxyl radicals, and the half-life of this process is approximately 8 days. DBNPA is also susceptible to photolysis in the atmosphere, directly.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.